Prevention and management of neutropenic sepsis in patients with cancer: summary of NICE guidance

Neutropenic Sepsis (NS) is a well recognised treatment complication, typically occurring 7-10 days following cancer cytotoxic chemotherapy. Colleagues in acute medicine will be only too familiar with the scenario of cancer patients that present with fever in the absence of localising signs and symptoms and with a very low yield from microbiological cultures. The incidence and mortality of NS are poorly defined and historically, management guidelines have often been developed in relative isolation from the broader subject of infection and sepsis care. Despite the lack of a clear and pragmatic definition, NICE guidance CG151 (2012) identified suspected NS as a medical emergency requiring prompt empirical broad spectrum antibiotics.

Download Full-text

Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial

Trials ◽

10.1186/s13063-020-04241-1 ◽

2020 ◽

Vol 21 (1) ◽

Author(s):

Caroline Forde ◽

Ronan McMullan ◽

Mike Clarke ◽

Richard H. Wilson ◽

Ruth Plummer ◽

...

Keyword(s):

Randomised Controlled Trial ◽

Antibiotic Therapy ◽

Study Protocol ◽

Controlled Trial ◽

Low Risk ◽

Oral Antibiotic ◽

Patients With Cancer ◽

Neutropenic Sepsis ◽

Oral Antibiotic Therapy ◽

Randomised Controlled

Download Full-text

Acoustic Changes in Chinese Patients With Cancer-Related Unilateral Vocal Fold Paralysis After Medialization Thyroplasty

Contemporary Issues in Communication Science and Disorders ◽

10.1044/cicsd_35_s_17 ◽

2008 ◽

Vol 35 (Spring) ◽

pp. 17-24 ◽

Cited By ~ 4

Author(s):

Manwa L. Ng ◽

Ripley K. Wong ◽

William I. Wei ◽

Y. H. Wong ◽

Paul K. Y. Lam

Keyword(s):

Vocal Fold ◽

Vocal Fold Paralysis ◽

Chinese Patients ◽

Unilateral Vocal Fold Paralysis ◽

Patients With Cancer ◽

Medialization Thyroplasty

Download Full-text

A reappraisal of staging and therapy for patients with cancer of the rectum. II. Patterns of presentation and outcome of treatment

Archives of Internal Medicine ◽

10.1001/archinte.135.11.1454 ◽

1975 ◽

Vol 135 (11) ◽

pp. 1454-1462 ◽

Cited By ~ 3

Author(s):

A. R. Feinstein

Keyword(s):

Cancer Of The Rectum ◽

Patients With Cancer

Download Full-text

L-arginine effect on inflammatory mediators: A systematic review of randomized controlled clinical trials

International Journal for Vitamin and Nutrition Research ◽

10.1024/0300-9831/a000619 ◽

2019 ◽

pp. 1-9 ◽

Cited By ~ 1

Author(s):

Seyed Reza Mirhafez ◽

Mitra Hariri

Keyword(s):

Systematic Review ◽

Clinical Trials ◽

Inflammatory Mediators ◽

Randomized Clinical Trials ◽

Randomized Controlled Clinical Trials ◽

Patients With Cancer ◽

Reactive Protein ◽

Randomized Controlled ◽

Human Adults ◽

Factor Α

Abstract. L-arginine is an important factor in several physiological and biochemical processes. Recently, scientists studied L-arginine effect on inflammatory mediators such as C-reactive protein (CRP), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). We conducted a systematic review on randomized controlled trials assessing L-arginine effect on inflammatory mediators. We searched data bases including Google scholar, ISI web of science, SCOPUS, and PubMed/Medline up to April 2019. Randomized clinical trials assessing the effect of L-arginine on inflammatory mediators in human adults were included. Our search retrieved eleven articles with 387 participants. Five articles were on patients with cancer and 6 articles were on adults without cancer. L-arginine was applied in enteral form in 5 articles and in oral form in 6 articles. Eight articles were on both genders, two articles were on women, and one article was on men. L-arginine could not reduce inflammatory mediators among patients with and without cancer except one article which indicated that taking L-arginine for 6 months decreased IL-6 among cardiopathic nondiabetic patients. Our results indicated that L-arginine might not be able to reduce selected inflammatory mediators, but for making a firm decision more studies are needed to be conducted with longer intervention duration, separately on male and female and with different doses of L-arginine.

Download Full-text

Are Three Items Sufficient to Measure Sense of Coherence?

European Journal of Psychological Assessment ◽

10.1027/1015-5759/a000337 ◽

2018 ◽

Vol 34 (4) ◽

pp. 229-237 ◽

Cited By ~ 2

Author(s):

Francesca Chiesi ◽

Andrea Bonacchi ◽

Caterina Primi ◽

Alessandro Toccafondi ◽

Guido Miccinesi

Keyword(s):

Sense Of Coherence ◽

Convergent Validity ◽

Clinical Sample ◽

Clinical Samples ◽

Depression Symptoms ◽

Time Saving ◽

Positive Role ◽

Patients With Cancer ◽

Measure Sense

Abstract. The present study aimed at evaluating if the three-item sense of coherence (SOC) scale developed by Lundberg and Nystrom Peck (1995) can be effectively used for research purpose in both nonclinical and clinical samples. To provide evidence that it represents adequately the measured construct we tested its validity in a nonclinical (N = 658) and clinical sample (N = 764 patients with cancer). Results obtained in the nonclinical sample attested a positive relation of SOC – as measured by the three-item SOC scale – with Antonovsky’s 13-item and 29-item SOC scales (convergent validity), and with dispositional optimism, sense of mastery, anxiety, and depression symptoms (concurrent validity). Results obtained in the clinical sample confirmed the criterion validity of the scale attesting the positive role of SOC – as measured by the three-item SOC scale – on the person’s capacity to respond to illness and treatment. The current study provides evidence that the three-item SOC scale is a valid, low-loading, and time-saving instrument for research purposes on large sample.

Download Full-text